Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 181Lymphoma 97Lymphoma, Large B-Cell, Diffuse 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Sarcoma 69Hodgkin Disease 54Lymphoma, Non-Hodgkin 41Triple Negative Breast Neoplasms 37Burkitt Lymphoma 36Lymphoma, Mantle-Cell 32Leukemia 32Lymphoma, Follicular 30Multiple Myeloma 28Carcinoma, Hepatocellular 28Neoplasm Metastasis 23Ovarian Neoplasms 21Neoplasms 21Lymphoma, Large-Cell, Anaplastic 18Osteosarcoma 17Lymphoma, B-Cell 17Prostatic Neoplasms 16Neuroblastoma 15Lymphoma, T-Cell, Peripheral 15Urinary Bladder Neoplasms 14Recurrence 13Lymphoma, Large-Cell, Immunoblastic 13Inflammatory Breast Neoplasms 13Immunoblastic Lymphadenopathy 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Stomach Neoplasms 10

Interventions

raltitrexed 1lobaplatin 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver, Cancer of, Primary Resectable × Doxorubicin × Clear all
NCT05701436 2023-03-02

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Zhujiang Hospital

Phase 3 Unknown
144 enrolled

Liver, Cancer of, Primary Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡